Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 8;41(33):4003–4017. doi: 10.1038/s41388-022-02391-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Schematic diagram displaying the time course of tumor induction and treatment in mice. b Representation of tumor growth inhibition by PFK158 and PFKFB3 genetic down regulation c Physical morphology and tumor images of xenograft from each group are shown. d Effect of pharmacological and genetic down regulation of PFKFB3 on tumor growth in NSG mice (n = 10 per group) and final tumor weights from different groups are shown. e Western analysis of the effect of PFKFB3 deficiency on cancer stemness markers including Aldh1, CD133, CD44, and Sox2. f Western blot analysis was performed to assess phospho and total LATS1/MST1, YAP/TAZ, and ABCG2 expression in lysates from the randomly selected xenografts in each group. g Immunoblot analysis of proliferative and apoptotic markers expressions such as Ki67, cleaved caspase3 and PARP from tumors of each group. α-tubulin was used as loading control. Each bar represents the mean ± SD (n = 10), Significant value expressed as *p < 0.05, **p < 0.01, and ***p < 0.001 by comparing test groups with control group.